ACADIA Pharmaceuticals Inc logo

ACADIA Pharmaceuticals Inc Investor Relations Material

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on improving the lives of patients with serious central nervous system disorders. The Company has a clinical program to assess the safety, efficacy and pharmacokinetic profile of pimavanserin (RE-021), an investigational drug that acts as a selective serotonin 5-hydroxytryptamine 2A receptor inverse agonist (SSRI) to study the central serotonergic system pharmacology and physiology in healthy volunteers and patients with Parkinson's disease psychosis (PDP).

Latest company events

Q2 20222022-08-08
Q1 20222022-05-04
Q4 20212022-02-28
Q3 20212021-11-08
Q2 20212021-08-04
Q1 20212021-05-04

More about ACADIA Pharmaceuticals Inc

Ticker symbol

ACAD

Country

United States of America

About the company

https://www.acadia-pharm.com/

Investor Relations Page

https://ir.acadia-pharm.com/

Dig deeper into the ACADIA Pharmaceuticals Inc fundamentals on Quartr.

  • Conference calls from all over the world
  • Search for anything across all transcripts
  • Consensus estimates
  • Comprehensive financial data
  • Read the transcripts or scroll the deck
  • Slide decks and earnings reports
App store link
Android play link
Quartr app screenshot